Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma (Q36344279)

13 August 2017

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma (English)

1 reference

13 August 2017

6

Toni K Choueiri

1 reference

13 August 2017

Jose A Karam

1

1 reference

13 August 2017

Brian I Rini

2

1 reference

13 August 2017

Leticia Varella

3

1 reference

13 August 2017

Jorge A Garcia

4

1 reference

13 August 2017

Robert Dreicer

5

1 reference

13 August 2017

Eric Jonasch

7

1 reference

13 August 2017

Surena F Matin

8

1 reference

13 August 2017

Steven C Campbell

9

1 reference

13 August 2017

Christopher G Wood

10

1 reference

13 August 2017

Nizar M Tannir

11

1 reference

13 August 2017

language of work or name

English

0 references

publication date

17 December 2010

1 reference

13 August 2017

1 reference

13 August 2017

185

1 reference

13 August 2017

2

1 reference

13 August 2017

439-444

1 reference

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Sorafenib in advanced clear-cell renal-cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Debulking nephrectomy in metastatic renal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

The changing natural history of renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Renal cell carcinoma: resection of solitary and multiple metastases.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Surgical resection of renal cell carcinoma after targeted therapy.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4668716

Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma

22 September 2018

1 reference

12 December 2020

Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases

1 reference

12 December 2020

Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy

1 reference

12 December 2020

Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery

1 reference

12 December 2020

Efficacy of multimodality therapy in advanced renal cell carcinoma

1 reference

12 December 2020

10.1016/J.JURO.2010.09.086

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

1 reference